ERBB2 and breast cancer: Feng et al. (2023) reported 35% HRD prevalence using genomic scar scores (GSS) in a cohort of 147 chinese breast cancer patients, with a significantly higher rate of HRD positivity was observed in TNBC (60.5%) compared to other subtypes like Luminal A (5.3%), Luminal B (HER2-) (28.8%), and Luminal B (HER2+) (31.6%) [81].